Search

Your search keyword '"Ruetsch, R."' showing total 6 results
Start Over Author "Ruetsch, R."
6 results on '"Ruetsch, R."'

2. 13th Workshop of the Central European Division e.V. of the International Isotope Society

Author

Derdau, Volker, primary, Atzrodt, Jens, additional, Markó, István E., additional, Harwood, Simon J., additional, Moenius, Th., additional, Salter, R., additional, Wietfeld, B., additional, Burtscher, P., additional, Zueger, C., additional, Clayden, Jonathan, additional, Bordeaux, K., additional, Metz, Y., additional, Rodriguez, I., additional, Ruetsch, R., additional, Voges, R., additional, Gardiner, John M., additional, Stimpson, William, additional, Panchal, Nitesh, additional, Herbert, John, additional, Ellames, George J., additional, Beller, Matthias, additional, Kozempel, Ján, additional, Kadeřávek, Jan, additional, Lešetický, Ladislav, additional, Lebeda, Ondřej, additional, Wähälä, Kristiina, additional, Kiuru, Paula, additional, Leppälä, Eija, additional, Pohjoispää, Monika, additional, Parikka, Kirsti, additional, Raffaelli, Barbara, additional, Herbert, John M., additional, Janssen, Cor G. M., additional, Verluyten, Willy L. M., additional, Vliegen, Maarten, additional, Mäding, P., additional, Füchtner, F., additional, Bergmann, R., additional, Pietzsch, J., additional, Hultsch, C., additional, Wüst, F., additional, Scheunemann, M., additional, Vercouillie, J., additional, Fischer, St., additional, Sorger, D., additional, Großmann, U., additional, Schliebs, R., additional, Sabri, O., additional, and Steinbach, J., additional

Published
2006
Full Text
View/download PDF

3. 11th conference of the central european division e.V. of the international isotope society

Author

Pounds, S., primary, Hickey, M. J., additional, Kingston, L. P., additional, Mather, A. N., additional, Wilkinson, D. J., additional, Sidorov, G. V., additional, Zverkov, Yu. B., additional, Myasoedov, N. F., additional, Karpenko, I. L., additional, Shirokova, E. A., additional, Yanvarev, D. M., additional, Yasko, M. V., additional, Skoblov, Yu. S., additional, Susan, A. B., additional, Nagaev, I. Y., additional, Shevchenko, V. P., additional, Rotert, G., additional, Krüger, Jens, additional, Fels, Gregor, additional, Wuest, F., additional, Mäding, P., additional, Zessin, J., additional, Pleiß, U., additional, Wüst, F., additional, Bloom, A. J., additional, Derdau, V., additional, Oekonomopulos, R., additional, Schubert, G., additional, Andres, H., additional, Burtscher, P., additional, Metz, Y., additional, Moenius, Th., additional, Kaegi, F., additional, Rodriguez, I., additional, Ruetsch, R., additional, Janssen, C. G. M., additional, Verreet, B., additional, Lenoir, H. A. C., additional, Thijssen, J. B. A., additional, Stuerm, Rolf P., additional, Krins, Andreas, additional, Rausch, E., additional, Breyer, M., additional, Hucke, K., additional, Gaefke, D., additional, and Schmeer, K., additional

Published
2004
Full Text
View/download PDF

5. Positioning biologics in the treatment of IBD: A practical guide - Which mechanism of action for whom?

Author

Juillerat P, Grueber MM, Ruetsch R, Santi G, Vuillèmoz M, and Michetti P

Abstract

The number of available biological therapies have doubled over the last 10 years and the arrival of novel molecules (interleukin 23p19 inhibitors) is ongoing alongside the development of small molecules. As a result of this vast landscape of treatment, positioning advanced therapies (according to clinical situation, efficacy and safety) is of paramount importance to providing personalized, appropriate IBD treatment. In this publication the recent available literature is summarized for practical integration into clinical practice including comparative efficacy data, patient and disease demographics. We refer to recent publications and expert opinion in order to facilitate the decision making process of positioning biologicals IBD treatment., Competing Interests: Pascal Juillerat ​received consulting fees from AbbVie, Arena Pharma, Amgen, BMS, Ferring, Gilead, Janssen, Lilly, MSD, Pfizer, Pierre Fabre, Roche, Takeda, and Vifor Pharma. Lecture fees from AbbVie, Amgen, Janssen, Pfizer, Takeda, UCB pharma and Vifor Pharma and research grants from Vifor Pharma. ​Maude Martinho Grueber, Roseline Ruetsch, Giulia Santi and Marianne Vullièmoz ​have no conflict of interest to declare. ​Pierre Michetti ​received consulting fees from AstraZeneca, AbbVie, Ferring Pharmaceuticals, Janssen, MSD, Nestlé Health Sciences, Pfizer, Pierre Fabre, Takeda, UCB Pharma, and Vifor Pharma, lecture fees from Ferring Pharmaceuticals, Janssen, Hospira, MSD, Pfizer, Takeda, UCB Pharma, and Vifor Pharma and research grants from iQone., (© 2022 The Authors. Published by Elsevier B.V.)

Published
2022
Full Text
View/download PDF

6. [Does long-term use of proton pump inhibitors promote premalignant lesions of the gastric mucosa?].

Author

Ruetsch R, Juillerat P, Flatz A, and von Elm E

Subjects
Gastric Mucosa pathology, Humans, Long-Term Care, Male, Middle Aged, Precancerous Conditions diagnosis, Proton Pump Inhibitors therapeutic use, Randomized Controlled Trials as Topic, Risk Factors, Stomach Neoplasms diagnosis, Gastric Mucosa drug effects, Precancerous Conditions chemically induced, Proton Pump Inhibitors adverse effects, Stomach Neoplasms chemically induced
Published
2016
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results